Redox State of Human Serum Albumin and Inflammatory Biomarkers in Hemodialysis Patients with Secondary Hyperparathyroidism During Oral Calcitriol Supplementation for Vitamin D

Overview

Journal Open Med Chem J

Publisher Bentham Open

Specialty Biochemistry

Date 2018 Nov 20

PMID 30450134

Citations 12

Authors

Wesam A Nasif

Mohammed H Mukhtar

Hoda M El-Emshaty

Ahmed H Alwazna

Affiliations

Soon will be listed here.

Abstract

Background: Hemodialysis (HD) patients with secondary Hyperparathyroidism (s-HPT) are exposed to increased inflammation and oxidative stress. In HD patients, oxidized albumin is a reliable marker of oxidative stress and its clinical significance has been rarely studied.

Objective: The objective of this study was to evaluate Cys34 Human Serum Albumin (HSA) as oxidative stress biomarker in HD patients with s-HPT and its relationship with inflammation on bone turnover markers during oral calcitriol supplementation for vitamin D.

Patients And Methods: Fifteen stable hemodialysis patients with s-HPT (mean age 48.67±8.15, 11 males and 4 females) were used in the experiment to receive calcitriol treatment for 16 weeks (0.25mcg or 0.5 mcg once a day according to serum level of Ca and P for each). The changes in the serum biochemical parameters (Ca, P, ALP, and iPTH), inflammatory markers (CRP and IL-6 levels) and serum oxidative stress condition (SOD, IS and albumin ratio HNA/HMA) were evaluated before and at 8 and 16 weeks of calcitriol treatment. The correlations between those factors were studied.

Results: All patients responded to oral calcitriol therapy, with a significant decrease in the serum iPTH. The results showed that calcitriol could effectively suppress iPTH secretion with a significant elevation of serum Ca and P but ALP remained unchanged during the study. It can also effectively reduce the inflammatory markers (CRP and IL-6), while increasing the oxidative markers (SOD and IS). Oxidative albumin ratio HNA/HMA showed a significant (=0.001) reduction after 16 weeks of calcitriol treatment and the redox state of HSA showed a positive prediction for hyperparathyroidism and for inflammation.

Conclusion: The redox state of HSA could be used as a predictor for monitoring hyperparathyroidism and inflammation during calcitriol treatment by retarding albumin oxidation in HD patients with secondary hyperparathyroidism.

Citing Articles

Reducing the levels of indoxyl sulfate in patients undergoing dialysis: a promising approach to managing inflammation and the redox state of human serum albumin.

Nasif W, Mokhtar M, Ewis A, Al-Amodi H, Ali A J Med Life. 2024; 17(8):791-799.

PMID: 39539435 PMC: 11556519. DOI: 10.25122/jml-2023-0538.

Association of ratios of visceral fat area/subcutaneous fat area and muscle area/standard body weight at T12 CT level with the prognosis of acute respiratory distress syndrome.

Shen H, He Y, Lu F, Lu X, Yang B, Liu Y Chin Med J Pulm Crit Care Med. 2024; 2(2):106-118.

PMID: 39169930 PMC: 11332858. DOI: 10.1016/j.pccm.2024.05.004.

Oxidised Albumin Levels in Plasma and Skeletal Muscle as Biomarkers of Disease Progression and Treatment Efficacy in Dystrophic Mice.

Terrill J, Bautista A, Tsioutsias I, Grounds M, Arthur P Antioxidants (Basel). 2024; 13(6).

PMID: 38929159 PMC: 11201235. DOI: 10.3390/antiox13060720.

Exploring Albumin Functionality Assays: A Pilot Study on Sepsis Evaluation in Intensive Care Medicine.

Klinkmann G, Waterstradt K, Klammt S, Schnurr K, Schewe J, Wasserkort R Int J Mol Sci. 2023; 24(16).

PMID: 37628734 PMC: 10454468. DOI: 10.3390/ijms241612551.

HSA Adductomics Reveals Sex Differences in NHL Incidence and Possible Involvement of Microbial Translocation.

Grigoryan H, Imani P, Sacerdote C, Masala G, Grioni S, Tumino R Cancer Epidemiol Biomarkers Prev. 2023; 32(9):1217-1226.

PMID: 37409972 PMC: 10529301. DOI: 10.1158/1055-9965.EPI-23-0231.

References

Izquierdo M, Cavia M, Muniz P, de Francisco A, Arias M, Santos J . Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients. BMC Nephrol. 2012; 13:159. PMC: 3520723. DOI: 10.1186/1471-2369-13-159. View

Mera K, Anraku M, Kitamura K, Nakajou K, Maruyama T, Otagiri M . The structure and function of oxidized albumin in hemodialysis patients: Its role in elevated oxidative stress via neutrophil burst. Biochem Biophys Res Commun. 2005; 334(4):1322-8. DOI: 10.1016/j.bbrc.2005.07.035. View

Anraku M, Kitamura K, Shinohara A, Adachi M, Suenga A, Maruyama T . Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int. 2004; 66(2):841-8. DOI: 10.1111/j.1523-1755.2004.00813.x. View

Wu C, Chang J, Chen C, Su S, Yang L, Ma W . Calcitriol treatment attenuates inflammation and oxidative stress in hemodialysis patients with secondary hyperparathyroidism. Tohoku J Exp Med. 2011; 223(3):153-9. DOI: 10.1620/tjem.223.153. View

Jaqueto M, Delfino V, Bortolasci C, Barbosa D, Morimoto H, Frange R . Are PTH levels related to oxidative stress and inflammation in chronic kidney disease patients on hemodialysis?. J Bras Nefrol. 2016; 38(3):288-295. DOI: 10.5935/0101-2800.20160045. View

Schieppati A, Perna A, Zamora J, Giuliano G, Braun N, Remuzzi G . Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev. 2004; (4):CD004293. DOI: 10.1002/14651858.CD004293.pub2. View

Ziouzenkova O, Sevanian A . Oxidative modification of low-density lipoprotein (LDL) in HD patients: role in electronegative LDL formation. Blood Purif. 2000; 18(3):169-76. DOI: 10.1159/000014415. View

Shimoishi K, Anraku M, Kitamura K, Tasaki Y, Taguchi K, Hashimoto M . An oral adsorbent, AST-120 protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure. Pharm Res. 2007; 24(7):1283-9. DOI: 10.1007/s11095-007-9248-x. View

Alborzi P, Patel N, Peterson C, Bills J, Bekele D, Bunaye Z . Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension. 2008; 52(2):249-55. DOI: 10.1161/HYPERTENSIONAHA.108.113159. View

10.

Himmelfarb J, McMonagle E . Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int. 2001; 60(1):358-63. DOI: 10.1046/j.1523-1755.2001.00807.x. View

11.

Grey A, Mitnick M, Shapses S, Ellison A, Gundberg C, Insogna K . Circulating levels of interleukin-6 and tumor necrosis factor-alpha are elevated in primary hyperparathyroidism and correlate with markers of bone resorption--a clinical research center study. J Clin Endocrinol Metab. 1996; 81(10):3450-4. DOI: 10.1210/jcem.81.10.8855783. View

12.

Blind E, Schmidt-Gayk H, Scharla S, Flentje D, Fischer S, Gohring U . Two-site assay of intact parathyroid hormone in the investigation of primary hyperparathyroidism and other disorders of calcium metabolism compared with a midregion assay. J Clin Endocrinol Metab. 1988; 67(2):353-60. DOI: 10.1210/jcem-67-2-353. View

13.

Pergola P, Raskin P, Toto R, Meyer C, Huff J, Grossman E . Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011; 365(4):327-36. DOI: 10.1056/NEJMoa1105351. View

14.

Descamps-Latscha B, Witko-Sarsat V . Importance of oxidatively modified proteins in chronic renal failure. Kidney Int Suppl. 2001; 78:S108-13. DOI: 10.1046/j.1523-1755.2001.59780108.x. View

15.

Anraku M, Chuang V, Maruyama T, Otagiri M . Redox properties of serum albumin. Biochim Biophys Acta. 2013; 1830(12):5465-72. DOI: 10.1016/j.bbagen.2013.04.036. View

16.

Judd S, Tangpricha V . Vitamin d therapy and cardiovascular health. Curr Hypertens Rep. 2011; 13(3):187-91. DOI: 10.1007/s11906-011-0190-2. View

17.

Descamps-Latscha B, Drueke T, Witko-Sarsat V . Dialysis-induced oxidative stress: biological aspects, clinical consequences, and therapy. Semin Dial. 2001; 14(3):193-9. DOI: 10.1046/j.1525-139x.2001.00052.x. View

18.

Cheng S, Liu C, Liu T, Hsu Y, Lee J . Association between parathyroid hormone levels and inflammatory markers among US adults. Mediators Inflamm. 2014; 2014:709024. PMC: 3980926. DOI: 10.1155/2014/709024. View

19.

Eleftheriadis T, Kartsios C, Antoniadi G, Kazila P, Dimitriadou M, Sotiriadou E . The impact of chronic inflammation on bone turnover in hemodialysis patients. Ren Fail. 2008; 30(4):431-7. DOI: 10.1080/08860220801964251. View

20.

Kalantar-Zadeh K, Brennan M, Hazen S . Serum myeloperoxidase and mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2006; 48(1):59-68. DOI: 10.1053/j.ajkd.2006.03.047. View